Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Autor:	James S Talks, Irini Chatziralli, Shane O. Regan, Sobha Sivaprasad, Ryian Mohamed
Rok vydání:	2018
Předmět:	Male medicine.medical_specialty Pediatrics Visual acuity genetic structures Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors Article Macular Degeneration 03 medical and health sciences 0302 clinical medicine Age related medicine Humans In patient 030212 general & internal medicine Retrospective Studies Aflibercept Aged 80 and over business.industry Retrospective cohort study Macular degeneration medicine.disease Choroidal Neovascularization Ophthalmology Receptors Vascular Endothelial Growth Factor Intravitreal Injections Cohort 030221 ophthalmology & optometry Female Outcomes research medicine.symptom business medicine.drug
Zdroj:	Eye. 32:1523-1529
ISSN:	1476-5454 0950-222X
DOI:	10.1038/s41433-018-0114-3
Popis:	PURPOSE: The purpose of this study was to investigate the efficacy of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) in very elderly patients aged 90 years or older at 2 years after treatment initiation. METHODS: In this multicentre retrospective data analysis from electronic medical record, consecutive treatment-naive patients with nAMD treated with aflibercept with at least 2 years follow-up were stratified into those aged
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fb4514c99d4e949c7ea81f00190030 https://doi.org/10.1038/s41433-018-0114-3 Zobrazit plný text záznamu Full text from SpringerLink